



STARPHARMA SUBSIDIARY APPOINTS CHIEF EXECUTIVE OFFICER

Melbourne (Australia) 21 November 2002: Starpharma Pooled Development Limited (ASX:SPL) is pleased to announce that its US subsidiary company Dendritic Nanotechnologies Limited (DNT) has appointed Charles Burke, PhD, as founding Chief Executive Officer.

Dr Burke brings substantial experience in biotechnology and business planning. He spent 15 years at Abbott Laboratories, during which the company grew from a small, technically based provider of hospital and laboratory diagnostic testing methods to a worldwide leader in diagnostics. Dr Burke established and led Abbott's "Venture" group, which was responsible for developing highly successful diagnostic products such as the TDx therapeutic drug analyzer, and for building a product line that generates sales worth over \$1 billion.

Dr Burke has also been associated with the growth and development of a number of other successful companies, leading diagnostic research teams in the development and commercialisation of major product lines and helping establish marketing strategies for new diagnostic products and technologies. He was CEO of Research Biochemicals, Inc., (RBI), a neuro-active research reagent company, that was sold to Sigma Aldrich in 1997. Most recently, Dr Burke was Founder and President of Monument Partners, Inc., a Boston-based consulting company involved in assisting start-up corporations in biotechnology and dot-com markets to develop strategy, financing, business plans and venture funding.

Starpharma CEO John Raff said: "The appointment of Dr Burke provides DNT with the full range of business and commercial skills which complement the outstanding scientific base of the company's US founders."

Dr Burke will be based at DNT's laboratories at Central Michigan University, Mount Pleasant, Michigan.

As recently reported (25 October 2002), Starpharma was given approval by the Pooled Development Funds Registration Board to convert DNT from an Australian-registered company to a US entity in order to capture its full potential to attract US Government and private equity funding. Starpharma retains a major equity position in DNT and has exclusive commercialisation rights to all pharmaceutical applications arising from DNT intellectual property.

CONTACTS:

Dr John Raff
Chief Executive Officer
+61 3 8532 2701
www.starpharma.com

Mr Ben Rogers
Company Secretary
+61 3 8532 2702